Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–like Growth Factor I Receptor Monoclonal AntibodyDong Hoon Shin, Ho‐Young Lee|Molecular Cancer Therapeutics|2011Cited by 43
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancerDong Hoon Shin, Sang Soo Kim|Experimental & Molecular Medicine|2023Cited by 18
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancerDong Hoon Shin, Sang Soo Kim|Research Square|2023Cited by 1